Last reviewed · How we verify

Cannabis sativa L., folium cum flore

Albina Nowak, MD · Phase 1 active Small molecule

Cannabis sativa L., folium cum flore is a Small molecule drug developed by Albina Nowak, MD. It is currently in Phase 1 development. Also known as: Spasmolytic.

At a glance

Generic nameCannabis sativa L., folium cum flore
Also known asSpasmolytic
SponsorAlbina Nowak, MD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cannabis sativa L., folium cum flore

What is Cannabis sativa L., folium cum flore?

Cannabis sativa L., folium cum flore is a Small molecule drug developed by Albina Nowak, MD.

Who makes Cannabis sativa L., folium cum flore?

Cannabis sativa L., folium cum flore is developed by Albina Nowak, MD (see full Albina Nowak, MD pipeline at /company/albina-nowak-md).

Is Cannabis sativa L., folium cum flore also known as anything else?

Cannabis sativa L., folium cum flore is also known as Spasmolytic.

What development phase is Cannabis sativa L., folium cum flore in?

Cannabis sativa L., folium cum flore is in Phase 1.

Related